Amneal Pharmaceuticals' Reports Crexont Provides Clinical Benefit Over Rytary in Phase 4 Interim Results

MT Newswires Live06-05

Amneal Pharmaceuticals (AMRX) said Friday that interim results from its phase 4 study of Crexont to treat Parkinson's disease demonstrated substantial clinical benefit after patients switched to the drug from Rytary.

The biopharmaceutical company, which also owns Rytary, said Crexont provided significant increases in "Good On" time, and reductions in "Off" time, and improved motor symptom control.

"Good On" time refers to the amount of time without dyskinesia plus "on" time with non-troublesome dyskinesia, and is an indicator of successful motor symptom control, according to The Expert Institute for Parkinson's Disease, which is owned by Amneal.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2641148300?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-05 20:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2641148300","market":"hk","top_or_hot":-1,"title":"Amneal Pharmaceuticals' Reports Crexont Provides Clinical Benefit Over Rytary in Phase 4 Interim Results","media":"MT Newswires Live","content":"<html><body><p> Amneal Pharmaceuticals (AMRX) said Friday that interim results from its phase 4 study of Crexont to treat Parkinson's disease demonstrated substantial clinical benefit after patients switched to the drug from Rytary.</p><p>The biopharmaceutical company, which also owns Rytary, said Crexont provided significant increases in \"Good On\" time, and reductions in \"Off\" time, and improved motor symptom control.</p><p>\"Good On\" time refers to the amount of time without dyskinesia plus \"on\" time with non-troublesome dyskinesia, and is an indicator of successful motor symptom control, according to The Expert Institute for Parkinson's Disease, which is owned by Amneal.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Amneal Pharmaceuticals' Reports Crexont Provides Clinical Benefit Over Rytary in Phase 4 Interim Results</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAmneal Pharmaceuticals' Reports Crexont Provides Clinical Benefit Over Rytary in Phase 4 Interim Results\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-06-05 20:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Amneal Pharmaceuticals (AMRX) said Friday that interim results from its phase 4 study of Crexont to treat Parkinson's disease demonstrated substantial clinical benefit after patients switched to the drug from Rytary.</p><p>The biopharmaceutical company, which also owns Rytary, said Crexont provided significant increases in \"Good On\" time, and reductions in \"Off\" time, and improved motor symptom control.</p><p>\"Good On\" time refers to the amount of time without dyskinesia plus \"on\" time with non-troublesome dyskinesia, and is an indicator of successful motor symptom control, according to The Expert Institute for Parkinson's Disease, which is owned by Amneal.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AMRX","symbol_name":"Amneal Pharmaceuticals, Inc.","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2641148300","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2641148300","pubTimestamp":1780662628,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Amneal Pharmaceuticals  said Friday that interim results from its phase 4 study of Crexont to treat Parkinson's disease demonstrated substantial clinical benefit after patients switched to the drug from Rytary.The biopharmaceutical company, which also owns Rytary, said Crexont provided significant increases in \"Good On\" time, and reductions in \"Off\" time, and improved motor symptom control.\"Good On\" time refers to the amount of time without dyskinesia plus \"on\" time with non-troublesome dyskinesia, and is an indicator of successful motor symptom control, according to The Expert Institute for Parkinson's Disease, which is owned by Amneal.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"AMRX":"Amneal Pharmaceuticals, Inc.","BK4007":"制药"},"translate_title":"Amneal Pharmaceuticals报告Crexont在4期中期结果中比Rytary提供了临床益处","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AMRX":1},"content_text":"Amneal Pharmaceuticals (AMRX) said Friday that interim results from its phase 4 study of Crexont to treat Parkinson's disease demonstrated substantial clinical benefit after patients switched to the drug from Rytary.The biopharmaceutical company, which also owns Rytary, said Crexont provided significant increases in \"Good On\" time, and reductions in \"Off\" time, and improved motor symptom control.\"Good On\" time refers to the amount of time without dyskinesia plus \"on\" time with non-troublesome dyskinesia, and is an indicator of successful motor symptom control, according to The Expert Institute for Parkinson's Disease, which is owned by Amneal.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2641148300","isCrawlerRequest":true}